Mehta Analysis: China, A Populist Pharma Power
Executive Summary
With money pouring into biopharma in China, and regulatory reforms favoring market growth and R&D speed, western firms should watch their backs, warns Viren Mehta, founding partner of Mehta Partners LLC.
You may also be interested in...
Finance Watch: A Plethora Of Big Rounds, Led By Gossamer's $230m Series B
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased
The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
Bigger, Bolder, SMAR: Decoding China's All-In-One Regulatory Agency
A new era began April 10 with disappearance of China FDA and kickoff of State Administration for Market Regulation (SMAR), the so-called 'One-Stop' regulatory agency. Will the CFDA's innovation-encouraging policies continue? How will the new agency balance innovation and enforcement? Pink Sheet offers preliminary answers to these key questions and decode the new SMAR from five important aspects.